Physician profile
Thi Cao
NPI 1629794086
$3,521.45
in general payments reported to CMS, 2019-2025
20 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $204 · 2023: $1,266 · 2024: $1,724 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $513.69 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $500.16 | 2022-2024 | Azstarys |
| Abbvie INC. | $408.09 | 2023-2025 | |
| Tris Pharma INC | $391.67 | 2023-2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $276.12 | 2023-2024 | Caplyta |
| Lundbeck LLC | $267.90 | 2022-2024 | Rexulti, Brintellix |
| Otsuka America Pharmaceutical, INC. | $235.08 | 2022-2025 | Rexulti |
| Pfizer INC. | $203.92 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $128.74 | 2023-2024 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.53 | 2023-2024 | Trintellix |
| Aimmune Therapeutics, INC. | $104.22 | 2025 | Vowst |
| Vanda Pharmaceuticals INC. | $88.47 | 2022-2023 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $71.63 | 2022-2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $53.44 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $45.67 | 2023-2024 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $35.14 | 2022-2023 | Quviviq |
| Noven Pharmaceuticals, INC. | $25.16 | 2024 | Xelstrym |
| Alexion Pharmaceuticals, INC. | $17.14 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $14.53 | 2024 | Cobenfy |
| Harmony Biosciences LLC | $13.15 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thi Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.